Universität Wien
Warning! The directory is not yet complete and will be amended until the beginning of the term.

301908 VO Development of novel cancer immunotherapies (2026S)

from target identification through target validation to clinical trials

3.00 ECTS (2.00 SWS), SPL 30 - Biologie
Moodle

Registration/Deregistration

Note: The time of your registration within the registration period has no effect on the allocation of places (no first come, first served).
Register/Deregister for this course

Details

Language: English

Examination dates

Lecturers

Classes (iCal) - next class is marked with N

-digitale Lehre-
blocked., starts in april
more information follows

  • Monday 04.05. 16:00 - 17:30 Hörsaal IMBA 1030 Wien, Dr.-Bohr-Gasse 3
  • Tuesday 05.05. 16:00 - 17:30 Hörsaal IMBA 1030 Wien, Dr.-Bohr-Gasse 3
  • Monday 18.05. 16:00 - 17:30 Hörsaal IMBA 1030 Wien, Dr.-Bohr-Gasse 3
  • Monday 01.06. 16:00 - 17:30 Hörsaal IMBA 1030 Wien, Dr.-Bohr-Gasse 3
  • Monday 08.06. 16:00 - 17:30 Hörsaal IMBA 1030 Wien, Dr.-Bohr-Gasse 3
  • Monday 15.06. 16:00 - 17:30 Hörsaal IMBA 1030 Wien, Dr.-Bohr-Gasse 3
  • Friday 19.06. 09:00 - 18:00 BZB/Seminarraum 1/2, 6.Ebene 6.501/6.504, Dr.-Bohr-Gasse 9, 1030 Wien

Information

Aims, contents and method of the course

The aim of the lecture is to transport the basic molecular, cellular and technological knowledge that is important for our understanding of current resistance mechanisms occurring in current immunotherapies. In Part II I will discuss state of the art methods which are currently employed to enhance our understanding of these mechanisms at play.

Assessment and permitted materials

Written exam, alternative: presentation

Minimum requirements and assessment criteria

Understanding of the basic mechanisms of resistance development and of newest technologies

Examination topics

Reading list

Association in the course directory

MMEI II-3.2, MMB III-5a., MMEI III, M-WZB, MMB IV., MNEU V., MMIC 5,MES5

Last modified: Mo 18.05.2026 14:27